By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Takeda Pharmaceutical Company has licensed from CellCentric cancer-related epigenetic target technologies for development and commercialization.

Under the agreement, Takeda's Research Group will conduct therapeutic research on molecules that will be further developed by Millenium, the biopharmaceutical firm that Takeda acquired in 2008.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Nov
15
Sponsored by
Twist Bioscience

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.